Další formáty:
BibTeX
LaTeX
RIS
@proceedings{989260,
author = {Kolek, V. and Grygárková, I. and Chalupa, J. and Koubková, L. and Janásková, T. and Roubec, J. and Popelková, P. and Bártek, T. and Sixtová, D. and Pavlíková, E. and Vlásek, T. and Chaloupka, F. and Skřičková, Jana},
booktitle = {13th Central European Lung Cancer Conference},
doi = {http://dx.doi.org/10.1016/j.lungcan.2012.05.064},
keywords = {lung cancer; erlotinib},
language = {eng},
title = {Oral vinorelbine in combination with carboplatin in adjuvant chemotherapy of non-small cell lung cancer (NSCLC): A prospective multicentre study of feasibility, tolerability and short time survival},
year = {2012}
}
TY - CONF
ID - 989260
AU - Kolek, V. - Grygárková, I. - Chalupa, J. - Koubková, L. - Janásková, T. - Roubec, J. - Popelková, P. - Bártek, T. - Sixtová, D. - Pavlíková, E. - Vlásek, T. - Chaloupka, F. - Skřičková, Jana
PY - 2012
TI - Oral vinorelbine in combination with carboplatin in adjuvant chemotherapy of non-small cell lung cancer (NSCLC): A prospective multicentre study of feasibility, tolerability and short time survival
KW - lung cancer
KW - erlotinib
N2 - Adjuvant cisplatinum-based chemotherapy is recommended for routine use in patients with stages IIA, IIB, and IIIA of non small-cell lung cancer (NSCLC) after radical resection. Results in stage IB were not conclusive. Vinorelbine is a preferable associated drug in this indication and a randomized study proved the comparable effectiveness and tolerability of vinorelbine given both orally or intravenously (i.v.) in advanced NSCLC, meanwhile oral vinorelbine gives better comfort to patients. The tolerance of adjutant chemotherapy and implementation of planned dose intensity remains a substantial problem, which most likely reflects the difficulty associated with CDDP-based chemotherapy. NCIC CTG BR.10, IALT and ANITA trials reported treatment-related deaths, accounting for 0.8–1.7%. In ANITA trial, median of planned dose was 56.3% in NVB and 76.1% in CDDP. Only 50% of patients finished all of 4 cycles planned. New studies targeting more tolerable regimens are needed. CDDP-based treatment is preferred, but several studies showed similar effectiveness and better tolerance of the combination of carboplatin (AUC5) and paclitaxel, pemetrexed or vinorelbine. Only few data exist about vinorelbine given orally in adjuvant chemotherapy (ACT).
ER -
KOLEK, V., I. GRYGÁRKOVÁ, J. CHALUPA, L. KOUBKOVÁ, T. JANÁSKOVÁ, J. ROUBEC, P. POPELKOVÁ, T. BÁRTEK, D. SIXTOVÁ, E. PAVLÍKOVÁ, T. VLÁSEK, F. CHALOUPKA a Jana SKŘIČKOVÁ. Oral vinorelbine in combination with carboplatin in adjuvant chemotherapy of non-small cell lung cancer (NSCLC): A prospective multicentre study of feasibility, tolerability and short time survival. In \textit{13th Central European Lung Cancer Conference}. 2012. ISSN~0169-5002. Dostupné z: https://dx.doi.org/10.1016/j.lungcan.2012.05.064.
|
